Analyst Conference Summaries

Biotechnology Investor Aids

Vertex Pharmaceuticals
VRTX

conference date: April 29, 2021 @ 1:30 PM Pacific Time

Vertex Pharmaceuticals Poised For Long-Term Growth [Seeking Alpha, February 2, 2021]

Vertex Pharmaceuticals Is (Now) A Good Long-Term Investment [Seeking Alpha, June 26, 2019]

The $300,000 Drug [New York Times, July 18, 2014]

I Still Don't Like Vertex [June 24, 2014]

Analyst Call Notes by William P. Meyers
2021
Vertex
Q1 2021
     
April 29, 2021      
2020
Vertex
Q1 2020
Vertex
Q2 2020
Vertex
Q3 2020
Vertex
Q4 2020
April 29, 2020 July 30, 2020 Oct. 29, 2020 Feb. 1, 2021
2019
Vertex
Q1 2019
Vertex
Q2 2019
Vertex
Q3 2019
Vertex
Q4 2019
April 30, 2019 July 31, 2019 Oct. 30, 2019 Jan. 30, 2020
2018
Vertex
Q4 2018
May 26, 2018
July 25, 2018
Oct. 24, 2018
Feb. 5, 2019
2017
April 27, 2016
July 26, 2017
Oct. 25, 2017
January 31, 2018
2016
04/27/2016
07/27/2016
10/25/2016
01/25/2017
2015
04/29/2015
07/29/2014
10/28/2015
01/27/2016
2014
05/01/2014
07/29/2014
10/28/2014
01/28/2015 
2013
07/29/2013
10/29/2013 
01/29/2014

Vertex Pharmaceuticals: Dog Of The Nasdaq 100? [September 11, 2013]

Vertex Pharmaceuticals (VRTX) is a manufacturer of therapies for Cystic Fibrosis and other diseases.

Vertex Pharmaceuticals web site
Vertex Pharmaceuticals investor relations page


 

Search

More Analyst Conference Pages:

 AGEN
 AGIO
 ALNY
 ALXN
 AMAT
 AMGN
 APRE
 ARWR
 BIIB
 BMY
 CLDX
 CLSN
 DRNA
 EPZM
 GILD
 GLYC
 ILMN
 INCY
 INO
 IONS
 ISRG
 MCHP
 PLX
 REGN
 RNA
 SGEN
 SYRS
 TTPH
 VBLT
 VSTM
 XLRN

Disclaimer: Our analyst summaries may include both our condensations of statements made by company representatives and our own analysis. They are not covered by any warranty. We cannot guarantee anything said by company representatives is true. We try not to make errors, but it is possible. This is financial journalism, not investment advice

Copyright 2021 William P. Meyers